4
Changes in Ownership
Taysha Gene Therapies, Inc. Filed Acc 0001209191-22-023862
Options or other derivatives
- CMO and Head of R&D acquired 40,325 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| PRASAD SUYASH CMO and Head of R&D | 2022-04-06 | Grant or award · Employee Stock Option (right to buy) | +40,325 | 40,325 | D | ||
Loading xslF345X03/doc4.xml…